RiVax Ricin Toxin Vaccine Description
RiVax Ricin Toxin Vaccine is Soligenix's proprietary heat stable recombinant subunit vaccine developed to protect against exposure to ricin toxin. RiVax® contains a genetically altered version of a Ricin Toxin A (RTA) chain containing two mutations that inactivate the ricin molecule's toxicity, which was originally invented at the University of Texas Southwestern.
RiVax® uses Soligenix’s proprietary ThermoVax® technology that creates a thermostabilized vaccine candidate that can be stored at room temperature for extended periods, making it compatible with United States government stockpiling requirements.
The thermostabilized version of RiVax® is produced by lyophilizing (freeze-drying) the vaccine in individual vials to form a solid white cake. This removes water and other components from the material which would otherwise destabilize the protein. By using a proprietary process, the protein-aluminum combination remains intact.
The solid, lyophilized material can then be returned to a liquid form immediately before use by simply adding sterile water and mixing prior to injection. Because sterile water is also very common and very stable, this results in an extremely convenient product that can be stored for extended periods. Long-term storage and ease of use are key attributes for a product that may be stockpiled.
Soligenix, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need.
RiVax Ricin Toxin Vaccine Indication
RiVax Ricin Toxin Vaccine candidate is indicated to prevent death following exposure to a lethal dose of ricin toxin.
RiVax Ricin Toxin Vaccine Dosage
RiVax is administered as an intramuscular injection on 2 or 3 occasions, resulting in the adaptive immune system mounting an antibody response.
RiVax induces the adaptive immune system to produce antibodies that recognize and bind ricin toxin, preventing it from getting inside cells and killing them. After intramuscular injection with RiVax®, IgG and other antibodies are produced and circulate within the body and are able to mop up ricin whether it was inhaled, eaten, or injected.
RiVax Ricin Toxin Vaccine News
December 8, 2020 - RiVax Ricin Toxin Vaccine is pursuing approval under the US Food and Drug Administration (FDA) "Animal Rule," applied to products where testing in clinical efficacy trials would be unethical. In the case of a ricin toxin vaccine, the vaccine's testing would be unethical since it would require exposing humans to ricin toxin. According to the CDC, Ricin is a poison found naturally in castor beans. Ricin can be found in many forms, including powder, mist, pellet, and can also be dissolved in water. It is considered a weapon of terror based upon its stability and high potency and the fact that it is readily extracted from by-products of castor oil production.
RiVax Ricin Toxin Vaccine Clinical Trials
NCBI Phase 1: A pilot clinical trial of a recombinant ricin vaccine in normal humans.
Clinical Trial NCT00812071: Phase 1B Study of RiVax, a Vaccine to Prevent the Toxic Effects of Ricin (FDA-OPD) Study Completion Date - January 2012
NCBI Phase 1B: Pilot Phase IB Clinical Trial of an Alhydrogel-Adsorbed Recombinant Ricin Vaccine
These studies suggest that RiVax/alum is safe and induces higher titers of both total and neutralizing antibodies.